Aled Williams named Enthera CEO

6 May 2022
aled_williams_enthera

Enthera Pharmaceuticals, a privately-held Italian biotech developing biologics for selected autoimmune conditions based on the discovery of an apoptosis pathway, has named Aled Williams (pictured) chief executive.

Mr Williams has more than 25 years of experience as a senior executive in the biotech and pharma sectors, with a strong track record across multiple therapeutic areas.

He has been responsible for corporate and portfolio strategy, devising R&D and market access strategies, as well as leading commercial product launches.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology